172 related articles for article (PubMed ID: 25868746)
41. An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.
Tao W; South VJ; Diehl RE; Davide JP; Sepp-Lorenzino L; Fraley ME; Arrington KL; Lobell RB
Mol Cell Biol; 2007 Jan; 27(2):689-98. PubMed ID: 17101792
[TBL] [Abstract][Full Text] [Related]
42. Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.
Cox CD; Breslin MJ; Whitman DB; Coleman PJ; Garbaccio RM; Fraley ME; Zrada MM; Buser CA; Walsh ES; Hamilton K; Lobell RB; Tao W; Abrams MT; South VJ; Huber HE; Kohl NE; Hartman GD
Bioorg Med Chem Lett; 2007 May; 17(10):2697-702. PubMed ID: 17395460
[TBL] [Abstract][Full Text] [Related]
43. Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.
Theoclitou ME; Aquila B; Block MH; Brassil PJ; Castriotta L; Code E; Collins MP; Davies AM; Deegan T; Ezhuthachan J; Filla S; Freed E; Hu H; Huszar D; Jayaraman M; Lawson D; Lewis PM; Nadella MV; Oza V; Padmanilayam M; Pontz T; Ronco L; Russell D; Whitston D; Zheng X
J Med Chem; 2011 Oct; 54(19):6734-50. PubMed ID: 21899292
[TBL] [Abstract][Full Text] [Related]
44. Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP.
Coleman PJ; Schreier JD; Cox CD; Fraley ME; Garbaccio RM; Buser CA; Walsh ES; Hamilton K; Lobell RB; Rickert K; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo L; Prueksaritanont T; Li C; Mahan EA; Fernandez-Metzler C; Salata JJ; Hartman GD
Bioorg Med Chem Lett; 2007 Oct; 17(19):5390-5. PubMed ID: 17761419
[TBL] [Abstract][Full Text] [Related]
45. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP.
Rickert KW; Schaber M; Torrent M; Neilson LA; Tasber ES; Garbaccio R; Coleman PJ; Harvey D; Zhang Y; Yang Y; Marshall G; Lee L; Walsh ES; Hamilton K; Buser CA
Arch Biochem Biophys; 2008 Jan; 469(2):220-31. PubMed ID: 17999913
[TBL] [Abstract][Full Text] [Related]
46. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
47. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
Cox CD; Coleman PJ; Breslin MJ; Whitman DB; Garbaccio RM; Fraley ME; Buser CA; Walsh ES; Hamilton K; Schaber MD; Lobell RB; Tao W; Davide JP; Diehl RE; Abrams MT; South VJ; Huber HE; Torrent M; Prueksaritanont T; Li C; Slaughter DE; Mahan E; Fernandez-Metzler C; Yan Y; Kuo LC; Kohl NE; Hartman GD
J Med Chem; 2008 Jul; 51(14):4239-52. PubMed ID: 18578472
[TBL] [Abstract][Full Text] [Related]
48. Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors.
Matsuno K; Sawada J; Sugimoto M; Ogo N; Asai A
Bioorg Med Chem Lett; 2009 Feb; 19(4):1058-61. PubMed ID: 19167222
[TBL] [Abstract][Full Text] [Related]
49. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M
Invest New Drugs; 2012 Jun; 30(3):1088-95. PubMed ID: 21424701
[TBL] [Abstract][Full Text] [Related]
50. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
Luo L; Parrish CA; Nevins N; McNulty DE; Chaudhari AM; Carson JD; Sudakin V; Shaw AN; Lehr R; Zhao H; Sweitzer S; Lad L; Wood KW; Sakowicz R; Annan RS; Huang PS; Jackson JR; Dhanak D; Copeland RA; Auger KR
Nat Chem Biol; 2007 Nov; 3(11):722-6. PubMed ID: 17922005
[TBL] [Abstract][Full Text] [Related]
51. Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction.
Carbajales C; Prado MÁ; Gutiérrez-de-Terán H; Cores A; Azuaje J; Novio S; Nuñez MJ; Fernández-García B; Sotelo E; García-Mera X; Sánchez-Lazo P; Freire-Garabal M; Coelho A
Chembiochem; 2014 Jul; 15(10):1471-80. PubMed ID: 24943831
[TBL] [Abstract][Full Text] [Related]
52. Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds.
Oishi S; Watanabe T; Sawada J; Asai A; Ohno H; Fujii N
J Med Chem; 2010 Jul; 53(13):5054-8. PubMed ID: 20521839
[TBL] [Abstract][Full Text] [Related]
53. Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain.
Sheth PR; Shipps GW; Seghezzi W; Smith CK; Chuang CC; Sanden D; Basso AD; Vilenchik L; Gray K; Annis DA; Nickbarg E; Ma Y; Lahue B; Herbst R; Le HV
Biochemistry; 2010 Sep; 49(38):8350-8. PubMed ID: 20718440
[TBL] [Abstract][Full Text] [Related]
54. The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5.
Schiemann K; Finsinger D; Zenke F; Amendt C; Knöchel T; Bruge D; Buchstaller HP; Emde U; Stähle W; Anzali S
Bioorg Med Chem Lett; 2010 Mar; 20(5):1491-5. PubMed ID: 20149654
[TBL] [Abstract][Full Text] [Related]
55. Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
Yao W; Zhuo J; Burns DM; Xu M; Zhang C; Li YL; Qian DQ; He C; Weng L; Shi E; Lin Q; Agrios C; Burn TC; Caulder E; Covington MB; Fridman JS; Friedman S; Katiyar K; Hollis G; Li Y; Liu C; Liu X; Marando CA; Newton R; Pan M; Scherle P; Taylor N; Vaddi K; Wasserman ZR; Wynn R; Yeleswaram S; Jalluri R; Bower M; Zhou BB; Metcalf B
J Med Chem; 2007 Feb; 50(4):603-6. PubMed ID: 17256836
[TBL] [Abstract][Full Text] [Related]
56. Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP.
Roecker AJ; Coleman PJ; Mercer SP; Schreier JD; Buser CA; Walsh ES; Hamilton K; Lobell RB; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo LC; Li C; Fernandez-Metzler C; Mahan EA; Prueksaritanont T; Hartman GD
Bioorg Med Chem Lett; 2007 Oct; 17(20):5677-82. PubMed ID: 17766111
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and evaluation of a novel prodrug, a S-trityl-
Fukai R; Ogo N; Ichida T; Yamane M; Sawada JI; Miyoshi N; Murakami H; Asai A
Eur J Med Chem; 2021 Apr; 215():113288. PubMed ID: 33640763
[TBL] [Abstract][Full Text] [Related]
58. KSP inhibitors as antimitotic agents.
Pérez-Melero C
Curr Top Med Chem; 2014; 14(20):2286-311. PubMed ID: 25434354
[TBL] [Abstract][Full Text] [Related]
59. Synthesis of N-(1-(6-acetamido-5-phenylpyrimidin-4-yl) piperidin-3-yl) amide derivatives as potential inhibitors for mitotic kinesin spindle protein.
Muthuraja P; Himesh M; Prakash S; Venkatasubramanian U; Manisankar P
Eur J Med Chem; 2018 Mar; 148():106-115. PubMed ID: 29454915
[TBL] [Abstract][Full Text] [Related]
60. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
Nagarajan S; Skoufias DA; Kozielski F; Pae AN
J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
